Real-world Experience With Upadacitinib in Adolescents and Adults With Refractory Atopic Dermatitis: A 24-week Retrospective Study

Actas Dermosifiliogr. 2024 Jun;115(6):T615-T617. doi: 10.1016/j.ad.2024.04.001. Epub 2024 Apr 4.

[Article in English, Spanish]

Authors

J Naharro-Rodríguez¹, E Berná-Rico², F J Pérez-Bootello², B Pérez-García²

Affiliations

¹ Dermatology Department, Ramón y Cajal University Hospital, IRYCIS, Madrid, España. Electronic address: jorgenrmed@gmail.com.
² Dermatology Department, Ramón y Cajal University Hospital, IRYCIS, Madrid, España.

PMID: 38582299
DOI: 10.1016/j.ad.2024.04.001

No abstract available

Publication types

Letter
Case Reports

MeSH terms

Adolescent
Adult
Dermatitis, Atopic* / drug therapy
Female
Heterocyclic Compounds, 3-Ring* / therapeutic use
Humans
Male
Middle Aged
Retrospective Studies
Time Factors
Young Adult

Substances

upadacitinib
Heterocyclic Compounds, 3-Ring